CVR number 12582447
Industry 46.4620 Wholesale of pharmaceutical goods

ETAC IMMEDIA A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  6.5% 7.2% 6.0% 2.8% 6.0%  
Credit score (0-100)  36 32 38 59 39  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  25,683 26,323 39,098 26,914 25,263  
EBITDA  18,411 13,794 24,839 11,271 12,266  
EBIT  18,408 13,781 24,781 11,118 11,869  
Pre-tax profit (PTP)  17,511.4 13,050.7 24,780.3 11,889.7 12,110.7  
Net earnings  13,657.7 10,178.4 19,426.5 9,292.9 9,502.2  
Pre-tax profit without non-rec. items  17,511 13,051 24,780 11,890 12,111  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  60.0 61.5 357 3,269 225  
Shareholders equity total  17,015 13,536 22,784 12,650 12,860  
Interest-bearing liabilities  34.6 943 983 440 309  
Balance sheet total (assets)  24,591 17,214 28,849 17,191 15,996  
Net Debt  34.3 943 983 440 309  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  25,683 26,323 39,098 26,914 25,263  
Gross profit growth  32.4% 2.5% 48.5% -31.2% -6.1%  
Employees  10 19 21 22 18  
Employee growth %  42.9% 90.0% 10.5% 4.8% -18.2%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  24,591 17,214 28,849 17,191 15,996  
Balance sheet change%  36.8% -30.0% 67.6% -40.4% -7.0%  
Added value  18,411.2 13,794.0 24,838.9 11,176.3 12,266.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  57 -11 238 2,760 -3,441  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  71.7% 52.4% 63.4% 41.3% 47.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  86.5% 65.9% 107.6% 51.7% 73.1%  
ROI %  116.1% 85.2% 129.5% 64.2% 91.0%  
ROE %  89.7% 66.6% 107.0% 52.5% 74.5%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  69.2% 78.6% 79.0% 73.6% 80.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.2% 6.8% 4.0% 3.9% 2.5%  
Gearing %  0.2% 7.0% 4.3% 3.5% 2.4%  
Net interest  0 0 0 0 0  
Financing costs %  5,183.8% 149.5% 0.1% 0.3% 6.8%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  3.4 4.7 4.7 3.2 5.4  
Current Ratio  3.6 4.7 4.7 3.2 5.4  
Cash and cash equivalent  0.3 0.0 0.0 0.0 0.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  17,755.6 13,487.8 22,446.8 9,550.4 12,873.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  1,841 726 1,183 508 681  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  1,841 726 1,183 512 681  
EBIT / employee  1,841 725 1,180 505 659  
Net earnings / employee  1,366 536 925 422 528